β2-adrenoceptor agonists are the first-line treatment of asthma and chronic obstructive
pulmonary disease (COPD), in which a short-acting β2-adrenoceptor agonist is used as …

A total of 1,068 patients, aged 18-70 yrs, with mild to moderate reversible airways disease,
were recruited into a multicentre, double-blind, parallel group study in 76 European centres …

Background and aim Recently, β-blockers have been suggested as a potential maintenance
treatment option for asthma. The aim of this review is to provide an overview of the current …

Despite advancements in treatment, the incidence of asthma, asthma-related deaths and
hospitalizations for asthma have increased significantly during the past decade. Although …

There is unequivocal evidence that the combination of an inhaled corticosteroid (ICS)—ie
glucocorticoid—and an inhaled long‐acting β2‐adrenoceptor agonist (LABA) is superior to …

Regular treatment with both long-and short-acting β 2-agonists results in tolerance to their
bronchoprotective effects, although the relevance of this phenomenon in terms of long term …

Increasing prevalence and severity of asthma has prompted the development and
promulgation of various national and international guidelines for asthma management in …

The decision by the Food and Drug Administration to issue a “black box” warning for long-
acting β-agonists has been followed by a series of pharmacoepidemiological studies …

History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

This action is the most recent in a long history of concerns and controversies about the
safety of these agents. The changes are based on FDA's analyses of studies that …